Citicoline – a neuroprotector with proven  effects on glaucomatous disease

Chițu, Iulia; Tudosescu, Ruxandra; Costin, Leasu-Branet; Voinea, Liliana

doi:10.22336/rjo.2017.29

Cited by 39 publications

(20 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Well-designed randomized controlled trials will be required to determine the clinical efficacy of citicoline. Citicoline is also well-tolerated with reports of minor digestive tolerance after its use [82].…”

Section: Methodsmentioning

confidence: 99%

Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications

Фу

Kwok

Chan

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

Retinal ganglion cell (RGC) death is the central and irreversible endpoint of optic neuropathies. Current management of optic neuropathies and glaucoma focuses on intraocular pressure-lowering treatment which is insufficient. As such, patients are effectively condemned to irreversible visual impairment. This review summarizes experimental treatments targeting RGCs over the last decade. In particular, we examine the various treatment modalities and determine their viability and limitations in translation to clinical practice. Experimental RGC treatment can be divided into (1) cell replacement therapy, (2) neuroprotection, and (3) gene therapy. For cell replacement therapy, difficulties remain in successfully integrating transplanted RGCs from various sources into the complex neural network of the human retina. However, there is significant potential for achieving full visual restoration with this technique. Neuroprotective strategies, in the form of pharmacological agents, nutritional supplementation, and neurotrophic factors, are viable strategies with encouraging results from preliminary noncomparative interventional case series. It is important to note, however, that most published studies are focused on glaucoma, with few treating optic neuropathies of other etiologies. Gene therapy, through the use of viral vectors, has shown promising results in clinical trials, particularly for diseases with specific genetic mutations like Leber's hereditary optic neuropathy. This treatment technique can be further extended to nonhereditary diseases, through transfer of genes promoting cell survival and neuroprotection. Crucially though, for gene therapy, teratogenicity remains a significant issue in translation to clinical practice.

show abstract

Section: Methodsmentioning

confidence: 99%

Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications

Фу

Kwok

Chan

et al. 2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Citicoline is naturally present in all cells, serving as an intermediate in the biosynthesis of phosphatidylcholine, a component of biological membranes [43]. Citicoline has been one of the first neuroprotectors proposed [44], and has shown neuroprotective effects in Alzheimer disease, stroke, and Parkinson's disease, as well as in glaucoma and amblyopia [45]. Some citicoline neuroprotective effects are mediated by the restoration of phosphatidylcholine levels and maintainance of sphingomyelin and cardiolipin levels (constituent of the inner mitochondrial membrane, involved in the cell energetic metabolism); by anti-oxidant effects, due to the increase of glutathione reductase (GR) activity and glutathione (GSH) synthesis and the decrease of PLA2 activity and lipid peroxidation; by the restoration of Na+/ K+ ATPase activity, essential for the proper functioning of neurons and glial cells.…”

Section: Food Supplementsmentioning

confidence: 99%

Food Supplements in the Treatment of Ophthalmic Diseases: Preclinical and Clinical Studies

2020

J Pharmacol Pharm Res

View full text Add to dashboard Cite

Among the 2.2 billion people in the world affected by any type of eye condition, the World Health Organization estimates 196 million with Age-related Macular Degeneration (AMD), 146 million with diabetic retinopathy (DR) and 76 million with glaucoma [1]. No clear estimate exists on the global presence of dry eye, though the English Agency known as Global-Data UK Ltd. in a document published on June 2018, considering the 8 more industrialised Countries (US,

show abstract

“…In connection with the above, when selecting the combinations of pharmacological agents for the study, the choice was made in favor of citicoline because of its ability to inhibit phospholipase A2, to modulate the release of various neurotransmitters, promoting neuroregeneration, and to inhibit apoptosis through the mitochondrial mechanisms (Iulia et al 2017;Gandolfi et al 2020;Jasielski et al 2020). Another medication to be logically included in the complex therapy is trimetazidine, which has anti-exitotoxic, anti-apoptotic and anti-ischemic effects.…”

Section: Introductionmentioning

confidence: 99%

A new EPOR/CD131 heteroreceptor agonist EP-11-1: a neuroprotective effect in experimental traumatic brain injury

Antsiferov¹,

Cherevatenko²,

Корокин³

et al. 2021

RRP

View full text Add to dashboard Cite

Introduction: EP-11-1 (UEHLERALNSS) is a short-chain erythropoietin derivative without have erythropoietic activity. It was created by modifying a peptide mimicking the spatial structure of the erythropoietin a-helix B pHBSP. One of the promising directions of its administration is the correction of morphofunctional disorders that occur in traumatic brain injury (TBI). Materials and methods: The study was performed in 160 male Wistar rats, weighing 180–200 g.TBI was simulated using the drop-weight method. To assess the emerging morphofunctional disorders and a degree of their correction, we used the severity of neurological deficit, indicators of locomotor activity and exploration, a marker of brain injury S100B and morphological examination. Results and discussion: The combined administration of a new EPOR/CD131 heteroreceptor agonist EP-11-1 with citicoline and trimetazidine led to a more pronounced correction of the neurological deficit when compared not only to the group of the ”untreated” animals, but also to the groups of animals to which these drugs had been administered as monotherapy (p < 0.05). The same tendency was also observed in the study of locomotor activity and exploration. A biochemical study showed that the administration of all three combinations led to a statistically significant (p < 0.05) decrease in the S-100B concentration compared not only to the group of “untreated” animals, but also to the groups of animals to which these drugs had been administered as a monotherapy. Conclusion: The results of the conducted experiments prove the most pronounced positive dynamics in the combined administration of the new EPOR/CD131 heteroreceptor agonist EP-11-1with citicoline and trimetazidine.

show abstract

Citicoline – a neuroprotector with proven effects on glaucomatous disease

Cited by 39 publications

References 23 publications

Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications

Therapeutic Strategies for Attenuation of Retinal Ganglion Cell Injury in Optic Neuropathies: Concepts in Translational Research and Therapeutic Implications

Food Supplements in the Treatment of Ophthalmic Diseases: Preclinical and Clinical Studies

A new EPOR/CD131 heteroreceptor agonist EP-11-1: a neuroprotective effect in experimental traumatic brain injury

Contact Info

Product

Resources

About